Beilu Pharmaceutical Co., Ltd.

Legal Opinion on the 2025 Shareholders' Meeting of Beijing Beilu Pharmaceutical Co., Ltd.

Announcement of Shareholders' Meeting Resolutions for 2025

Pre-disclosure announcement regarding the reduction of shares by senior management

CITIC Construction Investment Securities Co., Ltd. on the Verification Opinion for Beijing Beilu Pharmaceutical Co., Ltd. Using Temporarily Idle Raised Funds for Cash Management

Announcement on the Use of Temporarily Idle Raised Funds for Cash Management

Company Articles of Association

Announcement on changing registered capital, amending the 'Articles of Association', and handling industrial and commercial change registration

Announcement on adjusting the amount of raised funds intended for investment in fundraising projects

Verification opinion from CITIC Jiantou Securities Co., Ltd. on Beijing Beilu Pharmaceutical Co., Ltd. adjusting the amount of raised funds intended for investment in fundraising projects

Verification opinion from CITIC Jiantou Securities Co., Ltd. on Beijing Beilu Pharmaceutical Co., Ltd. providing interest-free loans to wholly-owned subsidiaries using raised funds for implementing fundraising projects

Verification opinion from CITIC Jiantou Securities Co., Ltd. on Beijing Beilu Pharmaceutical Co., Ltd. using raised funds to replace self-raised funds for paid issuance expenses

Announcement on using raised funds to replace self-raised funds for paid issuance expenses

Announcement on providing interest-free loans to wholly-owned subsidiaries using raised funds for implementing fundraising projects

Announcement of resolutions from the 11th meeting of the 9th Board of Directors

Announcement on the Signing of the Tripartite Supervision Agreement for Fundraising

Announcement on the Approval of Hydrochloride Dacronin Chemical Raw Material Drug for Market Launch

Announcement on Obtaining the Drug Registration Certificate for Iodinated Oil Injection

Announcement on the cumulative amount of conversion shares of Wanshun Convertible Bond 2 reaching 20% of the total shares issued by the company before conversion

Announcement on the equity changes due to the passive dilution of shareholding ratio of shareholders holding more than 5% reaching 1% multiples due to the company's issuance of stocks to specific objects

Announcement on the equity changes due to the passive dilution of shareholding ratio of the controlling shareholder and actual controller reaching 1% and 5% multiples due to the company's issuance of stocks to specific objects

Report from CITIC Securities Co., Ltd. on the compliance of the issuance process and subscription objects for the issuance of stocks to specific objects by Beijing Beilu Pharmaceutical Co., Ltd. in 2025 through a simplified procedure

Report on changes in shareholding of directors and senior management

Legal opinion letter from Beijing Zhonglun Law Firm regarding the compliance of the issuance process and subscription objects for the issuance of stocks to specific objects by Beijing Beilu Pharmaceutical Co., Ltd. through a simplified procedure

Sponsorship letter for the listing of stocks to specific objects in 2025 through a simplified procedure

Report on the issuance of stocks to specific objects in 2025 through a simplified procedure

Announcement on obtaining the 'Drug Registration Certificate' for mupirocin ointment

Announcement on the approval of gadobutrol chemical raw materials for market launch

Announcement on the addition of temporary proposals for the 2025 annual shareholders' meeting and supplementary notice for the shareholders' meeting

Prompt Announcement for the Disclosure of the 2026 First Quarter Report

CITIC Construction Investment Securities Co., Ltd. Verification Opinion on the Change of Part of the Use of Raised Funds, Implementation Entities, and Locations for Beijing Beilu Pharmaceutical Co., Ltd.

Announcement on Changes in Part of the Use of Raised Funds, Implementation Entities, and Locations

Resolution Announcement of the Ninth Board of Directors' Tenth Meeting

2026 First Quarter Report